Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0662-0419 in overweight or obesity
NCT07101783Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NNC0662-0419 in obesity (3 arms), sponsored by Novo Nordisk. Primary endpoint: Area Under the Plasma Concentration-Time Curve. Started Aug 2025; status: completed.
02
Drugs
NNC0662-0419
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07101783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101783.